Trial Profile
A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of FBS0701 in a Pediatric Population with Transfusional Iron Overload
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferitazole (Primary)
- Indications Iron overload
- Focus Pharmacokinetics
- Sponsors FerroKin BioSciences; Shire
- 07 Aug 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 26 Jun 2014 New trial record